Schrödinger Q2 2026 net income $6.0 million; software revenue down 10%, ACV up 27%
Schrödinger reported second quarter 2026 total revenue of $58.9 million, up 8%, and net income of $6.0 million, compared with a net loss of $43.2 million a year earlier. Net income was helped by a $45.9 million change in fair value of equity investments, and the company raised its 2026 drug discovery revenue guidance to $65 million to $75 million, though software revenue fell 10%.
Key points
- Total revenue was $58.9 million, up 8% from $54.8 million; diluted EPS was $0.08 versus a loss of $0.59 per share.
- Software revenue was $32.5 million, down 10%, which the company attributed to its transition to hosted software licensing.
- 2026 drug discovery revenue guidance was raised to $65 million to $75 million from $55 million to $65 million, tied to a $10 million Ajax Therapeutics collaboration milestone.
- 2026 ACV guidance is $218 million to $228 million, representing 10% to 15% growth over 2025.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.